Tarsus Pharmaceuticals (TARS) Short Interest Ratio & Short Volume → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free TARS Stock Alerts $32.21 -0.55 (-1.68%) (As of 04/25/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Tarsus Pharmaceuticals Short Interest DataCurrent Short Volume7,900,000 sharesPrevious Short Volume7,850,000 sharesChange Vs. Previous Month+0.64%Dollar Volume Sold Short$276.03 millionShort Interest Ratio / Days to Cover10.7Last Record DateApril 15, 2024Outstanding Shares34,220,000 sharesPercentage of Shares Shorted23.09%Today's Trading Volume371,844 sharesAverage Trading Volume722,233 sharesToday's Volume Vs. Average51% Short Selling Tarsus Pharmaceuticals ? Sign up to receive the latest short interest report for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatTARS Short Interest Over TimeTARS Days to Cover Over TimeTARS Percentage of Float Shorted Over Time Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. Tarsus Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20247,900,000 shares $276.03 million +0.6%N/A10.7 $34.94 3/31/20247,850,000 shares $285.35 million +9.0%N/A10.1 $36.35 3/15/20247,200,000 shares $227.38 million +19.4%N/A9.3 $31.58 2/29/20246,030,000 shares $230.47 million +6.5%N/A7.5 $38.22 2/15/20245,660,000 shares $178.57 million +4.2%N/A7.7 $31.55 1/31/20245,430,000 shares $147.91 million +8.2%N/A7.7 $27.24 Get the Latest News and Ratings for TARS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/20245,020,000 shares $110.94 million +0.4%N/A7.9 $22.10 12/31/20235,000,000 shares $101.25 million +1.8%N/A8.2 $20.25 12/15/20234,910,000 shares $93.54 million +10.3%N/A8.3 $19.05 11/30/20234,450,000 shares $73.56 million -0.2%N/A8.1 $16.53 11/15/20234,460,000 shares $79.97 million +6.2%N/A9.2 $17.93 10/31/20234,200,000 shares $59.81 million +5.0%N/A10.1 $14.24 10/15/20234,000,000 shares $51.92 million -19.4%N/A7.6 $12.98 9/30/20234,960,000 shares $88.14 million +13.0%N/A10.2 $17.77 9/15/20234,390,000 shares $70.85 million -2.7%N/A10.1 $16.14 8/31/20234,510,000 shares $78.97 million +0.7%N/A10.8 $17.51 8/15/20234,480,000 shares $76.16 million +17.9%N/A11.3 $17.00 7/31/20233,800,000 shares $83.64 million +65.9%N/A9.9 $22.01 7/15/20232,290,000 shares $40.42 million +2.2%13.0%10.7 $17.65 6/30/20232,240,000 shares $40.48 million +42.7%11.4%11 $18.07 6/15/20231,570,000 shares $29.23 million +72.6%8.0%7.8 $18.62 5/31/2023909,800 shares $15.24 million +6.8%4.7%5.5 $16.75 5/15/2023852,000 shares $14.11 million -11.3%4.4%6.2 $16.56 4/30/2023960,800 shares $14.34 million +0.2%5.0%8.7 $14.92 4/15/2023959,400 shares $11.10 million -3.3%5.0%9.3 $11.57 3/31/2023991,600 shares $12.46 million -4.7%5.2%12 $12.57 3/15/20231,040,000 shares $14.29 million +4.3%5.4%14.2 $13.74 2/28/2023996,700 shares $15.44 million +1.1%5.4%12 $15.49 2/15/2023985,900 shares $15.12 million +1.8%5.3%11.2 $15.34 1/31/2023968,800 shares $15.27 million -6.9%5.1%9.9 $15.76 1/15/20231,040,000 shares $15.12 million No Change5.5%9.7 $14.54 12/30/20221,040,000 shares $15.25 million +19.0%6.1%10.9 $14.66 12/15/2022874,300 shares $12.91 million -28.9%5.1%9.1 $14.77 11/30/20221,230,000 shares $20.68 million -3.2%7.2%12.8 $16.81 11/15/20221,270,000 shares $22.61 million -14.8%7.4%13.7 $17.80 10/31/20221,490,000 shares $27.45 million -0.7%8.9%16.6 $18.42 10/15/20221,500,000 shares $25.47 million +0.7%9.0%17.5 $16.98 9/30/20221,490,000 shares $25.51 million +19.2%8.9%17.4 $17.12 9/15/20221,250,000 shares $19.96 million No Change7.5%11.1 $15.97 8/31/20221,250,000 shares $19.23 million No Change7.5%10.6 $15.38A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. TARS Short Interest - Frequently Asked Questions What is Tarsus Pharmaceuticals' current short interest? Short interest is the volume of Tarsus Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 7,900,000 shares of TARS short. Learn More on Tarsus Pharmaceuticals' current short interest. What is a good short interest ratio for Tarsus Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TARS shares currently have a short interest ratio of 11.0. Learn More on Tarsus Pharmaceuticals's short interest ratio. Which institutional investors are shorting Tarsus Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Tarsus Pharmaceuticals: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Tarsus Pharmaceuticals' short interest increasing or decreasing? Tarsus Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 7,900,000 shares, an increase of 0.6% from the previous total of 7,850,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Tarsus Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Tarsus Pharmaceuticals: Scholar Rock Holding Co. (16.30%), Adaptimmune Therapeutics plc (0.34%), Autolus Therapeutics plc (1.53%), Vir Biotechnology, Inc. (5.79%), 4D Molecular Therapeutics, Inc. (19.21%), BioCryst Pharmaceuticals, Inc. (16.68%), Immatics (10.60%), ADMA Biologics, Inc. (3.55%), REGENXBIO Inc. (8.30%), Relay Therapeutics, Inc. (8.15%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Tarsus Pharmaceuticals stock? Short selling TARS is an investing strategy that aims to generate trading profit from Tarsus Pharmaceuticals as its price is falling. TARS shares are trading down $0.55 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Tarsus Pharmaceuticals? A short squeeze for Tarsus Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TARS, which in turn drives the price of the stock up even further. How often is Tarsus Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TARS, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Scholar Rock Short Interest Adaptimmune Therapeutics Short Interest Autolus Therapeutics Short Interest Vir Biotechnology Short Interest 4D Molecular Therapeutics Short Interest BioCryst Pharmaceuticals Short Interest Immatics Short Interest ADMA Biologics Short Interest REGENXBIO Short Interest Relay Therapeutics Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TARS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe AI stock to buy right nowStockEarnings